Infliximab and brucellosis: not the usual suspects, this time.
Tumor necrosis factor (TNF) plays an important role in the host defense mechanism, and anti-TNF antibody therapies may increase the risk of serious infections. We herein report a case of 57-year-old male with rheumatoid arthritis who developed brucellosis during treatment with infliximab in combination with methotrexate and a low-dose steroid. Brucellosis should be kept in mind, particularly in endemic areas, in patients receiving anti-TNF therapy. Clinicians should be aware of brucellosis symptoms and ways of contamination and should warn their patients. Early diagnosis and rapid treatment may prevent a possible poor course of the disease in immunocompromised patients.